A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.
Gui F, Jiang J, He Z, Li L, Li Y, Deng Z, Lu Y, Wu X, Chen G, Su J, Song S, Zhang YM, Yun CH, Huang X, Weisberg E, Zhang J, Deng X.
Gui F, et al. Among authors: huang x.
Br J Pharmacol. 2019 Dec;176(23):4491-4509. doi: 10.1111/bph.14809. Epub 2019 Dec 9.
Br J Pharmacol. 2019.
PMID: 31364164
Free PMC article.